

**Studien des Asklepios Tumorzentrum, Standort Altona**

Kurztitel	<b>MK3475-811</b>	Phase III
Indikation	<b>Magenkarzinom</b>	
Studientitel	A Phase III randomized, double-blind Trial comparing trastuzumab plus chemotherapy and pembrolizumab or Placebo as first-line Treatment in participants with HER2 positive metastatic gastric or gastroesophageal junction adenocarcinoma	
Sponsor	MSD Sharp & Dohme GmbH	
Status	Rekrutierend	

Kurztitel	<b>AIO-KRK-0214</b>	Phase II
Indikation	<b>Kolorektales Karzinom</b>	
Studientitel	mFOLFOX6 vs mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized Phase II-trial.	
Sponsor	AIO	
Status	Rekrutierend	

Kurztitel	<b>CANFOUR</b>	Phase II
Indikation	<b>Pankreaskarzinom</b>	
Studientitel	An open-Label, dose escalation followed by dose Expansion, safety and tolerability Trial of CAN04, a fully humanized monoclonal antibody against IL1RAP in subjects with solid malignant tumors.	
Sponsor	Cantargia	
Status	Rekrutierend	

Kurztitel	<b>INCMGA 0012-202 „PODIUM“</b>	Phase II
Indikation	<b>Analkarzinom</b>	
Studientitel	A Phase 2 study of INCMGA00012 in participants with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy.	
Sponsor	Incyte	
Status	Rekrutierend	

Kurztitel	<b>ANCHOR</b>	Phase II
Indikation	<b>Kolorektales Karzinom</b>	
Studientitel	Phase II, open-Label, single arm, multicenter study of encorafenib, binimetinib plus cetuximab in subjects with previously untreated BRAF-Mutant metastatic colorectal cancer.	
Sponsor	Pierre Fabre	
Status	Derzeit keine Rekrutierung, potentielle Patienten werden auf eine Warteliste aufgenommen.	